Mrs Julieanna Genoun Renner, MFT | |
439 Grand Ave, #195, Bigfork, MT 59911-3614 | |
(406) 837-0399 | |
Not Available |
Full Name | Mrs Julieanna Genoun Renner |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 439 Grand Ave, Bigfork, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1942442751 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 40913 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Julieanna Genoun Renner, MFT 439 Grand Ave, #195, Bigfork, MT 59911-3614 Ph: (406) 270-6516 | Mrs Julieanna Genoun Renner, MFT 439 Grand Ave, #195, Bigfork, MT 59911-3614 Ph: (406) 837-0399 |
News Archive
Higher levels of a protein called S-100 in patients with melanoma may correlate with a higher risk of having the disease return, say researchers at the University of Pittsburgh Cancer Institute (UPCI), who presented their findings today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Shooting steady pulses of electricity through slender electrodes into a brain area that controls complex behaviors has proven to be effective against several therapeutically stubborn neurological and neuropsychiatric disorders. Now, a new study has found that this technique, called deep brain stimulation (DBS), targets the same class of neuronal cells that are known to respond to physical exercise and drugs such as Prozac.
The Pancreatic Cancer Action Network today hosts its fourth annual Pancreatic Cancer Advocacy Day in Washington, D.C. Nearly 500 advocates, including patients, survivors and loved ones, from across the United States will meet with members of Congress to call for congressional action to ensure progress is made against the fourth leading cause of cancer death in our country by co-sponsoring the Pancreatic Cancer Research and Education Act.
Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. The company is focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through information-driven drug discovery, including GPCR structure. Investors include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
› Verified 4 days ago